reversed-phase HPLC comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2025-11-19. Numbers and descriptions here follow the published literature rather than marketing material.
Tirzepatide is a synthetic peptide that activates both the glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptors. This dual agonist profile distinguishes it from earlier incretin-based compounds that act on a single receptor. The molecule was engineered from the native GIP sequence and carries several non-natural residues that slow enzymatic breakdown. Researchers designed it to combine the insulinotropic effects of GIP signaling with the appetite and gastric-emptying effects associated with GLP-1 activation.
Development of tirzepatide took place under a research program that sought to test whether simultaneous engagement of two incretin receptors would produce greater metabolic effects than single-receptor agonism. Clinical trials were organized into the SURPASS series for type 2 diabetes and the SURMOUNT series for obesity and weight management. Regulatory clearance for type 2 diabetes came in 2022 in the United States, followed by approval for chronic weight management in 2023. The trial programs reported reductions in glycated hemoglobin and body weight relative to comparators, though long-term cardiovascular and durability data continue to accumulate.
The peptide backbone contains 39 amino acids and includes alpha-aminoisobutyric acid residues, which are not among the standard proteinogenic set. A C20 fatty diacid moiety is attached through a linker, allowing the compound to bind serum albumin and extend its circulation time. This albumin binding is the main reason the molecule supports once-weekly administration rather than more frequent dosing. The measured molecular mass is approximately 4,813 daltons, placing it firmly in the peptide rather than small-molecule class.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Modified synthetic peptide | 39-residue backbone with non-natural residues |
| Receptor targets | GIP and GLP-1 | Dual incretin receptor agonist |
| Approximate molecular mass | 4,813 Da | Calculated from the peptide sequence |
| Administration route | Subcutaneous injection | Weekly schedule in approved products |
| Albumin binding | Present | Mediated by a C20 fatty diacid side chain |
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Identity and purity assessment of tirzepatide relies primarily on reversed-phase high-performance liquid chromatography coupled with ultraviolet detection. Mass spectrometry, often in electrospray ionization mode, confirms the molecular mass and detects sequence-related impurities. Peptide mapping after enzymatic digestion provides residue-level confirmation of the backbone. Each method addresses a different question: chromatography for purity and related substances, mass measurement for identity, and mapping for sequence fidelity. No single technique covers all three.
Research and analytical settings increasingly require documentation of peptide origin and chain of custody. Certificate of analysis documents typically report purity by chromatographic area, mass confirmation, appearance, and residual solvent or counterion content. Independent verification by an accredited laboratory is common when a material will be used in a regulated study. Open questions remain about how well compendial methods transfer between laboratories, and about which impurity thresholds are meaningful for materials not intended for clinical use.
Identity and purity are established with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry for confirmation of the expected mass. Peptide mapping after enzymatic digestion verifies the primary sequence and detects substitutions. Size-exclusion chromatography quantifies aggregates and fragments, which are the impurities most often tracked for peptides of this size. Residual solvents, counterions, and water content fall under separate tests described in pharmacopeial chapters. Circular dichroism or nuclear magnetic resonance may be used in research settings to probe secondary structure, though such methods are less common in routine release testing.
Peptide active ingredients of this type are typically supplied as lyophilized powder because the dry form resists hydrolysis during transport. The material is hygroscopic, so vials are usually equilibrated to room temperature before opening to avoid condensation on the solid. Repeated freeze-thaw cycles can promote aggregation and are generally avoided by aliquoting stock into single-use portions. Personnel handling the powder work in controlled environments to limit inhalation of fine particles. Written procedures usually specify these steps rather than leaving them to individual judgment.
Clinical trials involving new drugs are commonly classified into five phases. Each phase of the drug approval process is treated as a separate clinical trial. The drug development process will normally proceed through phases I–IV over many years, frequently involving a decade or longer. If the drug successfully passes through phases I, II, and III, it will usually be approved by the national regulatory authority for use in the general population. Phase IV trials are performed after the newly approved drug, diagnostic or device is marketed, providing assessment about risks, benefits, or best uses.
== Medical uses == Racecadotril is used for the treatment of acute diarrhea in children and adults and has better tolerability than loperamide, as it causes less constipation and flatulence. Several guidelines have recommended racecadotril use in addition to oral rehydration treatment in children with acute diarrhea.
On April 25, 2023, Carrier Global announced that it intended to acquire the HVAC division Viessmann Climate Solutions from the Viessmann Group and divest its Commercial Refrigeration business and most of its Fire & Security businesses. In December 2023, Carrier Global sold its security businesses LenelS2, Supra and Onity to Honeywell for approximately $5 billion. In March 2025, Carrier Global declared to sell its Industrial Fire division to Sentinel Capital Partners in a $1.43 billion deal.
=== Airspheres === These are vast, brown dwarf-sized bubbles of atmosphere enclosed by force fields, and (presumably) set up by an ancient advanced race at least one and a half billion years ago (see: Look to Windward). There is only minimal gravity within an airsphere. They are illuminated by moon-sized orbiting planetoids that emit enormous light beams. Citizens of the Culture live there only very occasionally as guests, usually to study the complex ecosystem of the airspheres and the dominant life-forms: the "dirigible behemothaurs" and "gigalithine lenticular entities", which may be described as inscrutable, ancient intelligences looking similar to a cross between gigantic blimps and whales. The airspheres slowly migrate around the galaxy, taking anywhere from 50 to 100 million years to complete one circuit. In the novels no one knows who created the airspheres or why, but it is presumed that whoever did has long since sublimed but may maintain some obscure link with the behemothaurs and lenticular entities. Guests in the airspheres are not allowed to use any force-field technology, though no reason has been offered for this prohibition. The airspheres resemble in some respects the orbit-sized ring of breathable atmosphere created by Larry Niven in The Integral Trees, but spherical not toroidal, require a force field to retain their integrity, and arose by artificial rather than natural processes.
Sources: en.wikipedia.org
Retinol-binding proteins (RBP) are a family of proteins with diverse functions. They are carrier proteins that bind retinol. Assessment of retinol-binding protein is used to determine visceral protein mass in health-related nutritional studies. Retinol and retinoic acid play crucial roles in the modulation of gene expression and overall development of an embryo. However, deficit or excess of either one of these substances can cause early embryo mortality or developmental malformations. Regulation of transport and metabolism of retinol necessary for a successful pregnancy is accomplished via RBP. Retinol-binding proteins have been identified within the uterus, embryo, and extraembryonic tissue of the bovine, ovine, and porcine, clearly indicating that RBP plays a role in proper retinol exposure to the embryo and successful transport at the maternal-fetal interface. Further research is necessary to determine the exact effects of poor RBP expression on pregnancy and threshold levels for said expression.
Each intervention is evaluated simultaneously at all participating ITP sites using identical experimental protocols, animal husbandry practices, dosing regimens, and outcome measures, ensuring exceptional scientific rigor, reproducibility, and confidence in the results. Research conducted through the ITP has significantly advanced the field of geroscience by identifying interventions that reproducibly increase lifespan and improve measures of healthspan. Investigators evaluate a wide range of compounds and therapeutic strategies targeting key biological mechanisms of aging, including nutrient-sensing pathways, cellular senescence, mitochondrial function, proteostasis, inflammation, oxidative stress, autophagy, stem cell maintenance, and metabolic regulation. In addition to determining effects on longevity, studies assess functional outcomes such as physical performance, metabolic health, cardiovascular function, cognitive performance, cancer incidence, immune function, and age-related pathology. These comprehensive phenotypic assessments provide valuable insights into how interventions influence both lifespan and the quality of aging. The Barshop Institute's extensive aging research infrastructure substantially enhances the capabilities of the Interventions Testing Program.
1950s: Chinese-American medical scientist Tsai-Fan Yu co-founded a clinic at Mount Sinai Medical Center for the study and treatment of gout. Working with Alexander B. Gutman, Yu established that levels of uric acid were a factor in the pain experienced by gout patients, and subsequently developed multiple effective drugs for the treatment of gout. 1950: Chinese-American particle physicist Chien-Shiung Wu proved the validity of Quantum entanglement which counters Albert Einstein's EPR Paradox and published her work on the new year of the new decade. She also proved the validity of beta decay around this time. 1950: Ghanaian physician and science educator Matilda J. Clerk became the first woman in Ghana and West Africa to attend graduate school, earning a postgraduate diploma at the London School of Hygiene & Tropical Medicine. 1950: Isabella Abbott became the first Native Hawaiian woman to receive a PhD in any science; hers was in botany. 1950: American microbiologist Esther Lederberg became the first to isolate lambda bacteriophage, a DNA virus, from Escherichia coli K-12. 1951: American oncologist Jane C. Wright was the first to identify methotrexate, one of the foundational chemotherapy drugs, as an effective tool against cancerous tumors. 1951: Ghana's Esther Afua Ocloo became the first person of African ancestry to obtain a cooking diploma from the Good Housekeeping Institute in London and to take the post-graduate Food Preservation Course at Long Ashton Research Station, Department of Horticulture, Bristol University.
14 August – The annual Government Expenditure and Revenue Scotland report shows a public spending deficit of £22.7bn for Scotland during 2023, an increase of £3.6bn from the previous year. The Scottish Government confirms it will follow the UK government by scrapping universal winter fuel payments for pensioners, with the benefit to be means tested. Staff working on Edinburgh's tram network vote to take strike action over a lack of toilet breaks. 15 August – A shipwreck, believed to be that of HMS Hawke, which was sunk by a torpedo during World War I, has been found off the Aberdeenshire coast. 16 August – 2024 Scottish Conservatives leadership election: Four of the six candidates running for the position of Scottish Conservative leader call for the race to be paused after claims about Douglas Ross's behaviour as leader. The claims concern a report that in July 2023 Ross had asked for the leader of Moray council, Kathleen Robertson, to stand down as the prospective parliamentary candidate for Moray West, Nairn and Strathspey. Meghan Gallacher resigns as the party's deputy leader, citing a "potential risk to the reputation of our party and the leadership contest" after reports that Ross had previously suggested Russell Findlay should succeed him. Developers working on HM Prison Highland in Inverness have uncovered a prehistoric settlement believed to be around 2,000 years old.
Glycopyrronium bromide is a medication of the muscarinic anticholinergic group. It does not cross the blood–brain barrier and consequently has few to no central effects. It can be administered orally, intravenously, topically, or via inhalation. It is a synthetic quaternary ammonium compound. The cation, which is the active moiety, is called glycopyrronium (INN) or glycopyrrolate (USAN). The most common side effects include irritability, flushing, nasal congestion, reduced secretions in the airways, dry mouth, constipation, diarrhea, nausea and vomiting, and urinary retention. In September 2012, glycopyrronium was approved for medical use in the European Union. In June 2018, glycopyrronium was approved by the U.S. Food and Drug Administration (FDA) to treat excessive underarm sweating, becoming the first drug developed specifically to reduce excessive sweating. It is on the World Health Organization's List of Essential Medicines.
Sources: en.wikipedia.org
It binds and activates both the GIP and GLP-1 receptors, making it a dual incretin receptor agonist. Single-receptor GLP-1 agonists act on one target only. The dual profile is the defining pharmacological feature of the molecule.
A fatty diacid side chain promotes reversible binding to serum albumin. This association slows renal clearance and protects the peptide from rapid enzymatic degradation. The result is a prolonged circulation time that supports weekly administration.
The first regulatory approval, for type 2 diabetes, was granted in the United States in 2022. An additional approval for chronic weight management followed in 2023. Availability and approved indications vary by country and are set by each national regulator.
It activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. This dual activity separates it from agents that act on only one of the two receptors. The relative contribution of each receptor to clinical effects remains an open area of study.